10-Q: Vivos Therapeutics Reports Wider Losses Amid Strategic Pivot

Vivos Therapeutics, Inc. reported increased net losses and a significant cash burn for the first half of 2025, despite a strategic pivot towards acquiring and managing sleep treatment centers.

Summary

• Net loss for the three months ended June 30, 2025, increased to $5.013 million from $1.930 million in the prior year period.
• Net loss for the six months ended June 30, 2025, widened to $8.877 million from $5.692 million for the same period in 2024.
• Total revenue decreased by 6% to $3.820 million for the three months ended June 30, 2025, and by 9% to $6.835 million for the six months ended June 30, 2025.
• Gross profit margin declined to 55% for the three months and 53% for the six months ended June 30, 2025, compared to 65% and 61% respectively in 2024.
• General and administrative expenses surged by 55% to $6.409 million for the three months and 25% to $11.298 million for the six months ended June 30, 2025, primarily due to the SCN acquisition and integration costs.
• The company acquired The Sleep Center of Nevada (SCN) on June 10, 2025, for $8.7 million, funded by $6.0 million cash, $1.3 million in common stock, and a $1.4 million contingent earn-out.
• Cash and cash equivalents stood at $4.402 million as of June 30, 2025, down from $6.260 million at December 31, 2024.
• Net cash used in operating activities increased to $7.290 million for the six months ended June 30, 2025, from $5.564 million in the prior year.
• The company incurred $8.2 million in senior secured debt and raised $3.7 million through a private placement to fund the SCN acquisition and for working capital.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to significant and increasing net losses, declining revenue, and a stated 'substantial doubt' about the company's ability to continue as a going concern. While the strategic pivot and SCN acquisition are presented as positive long-term initiatives, their immediate financial impact is negative, contributing to higher expenses and debt. The unproven nature of the new model and past failures (Rebis Health) add to the uncertainty. The company's reliance on continuous capital raises underscores its precarious financial position.

Positives

• The acquisition of The Sleep Center of Nevada (SCN) marks a significant milestone in the company's strategic pivot to a direct patient-focused model, allowing for direct capture of diagnostic and consulting revenues.
• Initial patient demand at SCN is exceeding current capacity, suggesting potential for significant revenue growth once operational scaling is achieved.
• The company is actively developing a revised management model for collaborations with sleep centers, aiming for financial upside with limited capital expenditures and manageable risks.
• A new management agreement with MISleep Solution LLC in Auburn Hills, Michigan, is underway, with an estimated opening in October 2025, representing expansion under the revised model.
• The company has an expanding pipeline of potential acquisition and management opportunities with sleep centers and medical sleep specialists, driven by word-of-mouth.
• Net loss per share improved to $(0.55) for the three months and $(1.00) for the six months ended June 30, 2025, compared to $(0.60) and $(2.06) respectively in 2024, primarily due to a higher weighted average share count.

Negatives

• The company reported substantial doubt about its ability to continue as a going concern due to accumulated losses of $113.1 million and insufficient cash to fund operations for the next twelve months.
• Net losses significantly increased for both the three-month and six-month periods ended June 30, 2025, compared to the prior year.
• Total revenue declined, with a notable decrease in VIP enrollment revenue due to the strategic pivot away from the legacy business model.
• Gross profit and gross profit margins decreased, indicating higher costs relative to revenue.
• General and administrative expenses rose sharply, largely due to costs associated with the SCN acquisition and integration.
• The company incurred substantial new debt ($8.2 million senior secured note) to finance the SCN acquisition, increasing its total liabilities to $21.5 million.
• The prior contractual alliance with Rebis Health in Colorado did not meet revenue expectations due to ongoing delays beyond the company's control, highlighting risks with the new model.
• Patient demand at SCN is exceeding capacity, and the company does not expect to fully meet current demand until additional Sleep Optimization (SO) teams are deployed in 2026, indicating potential missed revenue opportunities in the near term.
• The company's ability to service its new substantial indebtedness is uncertain and depends on future financial and operating performance.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern due to accumulated losses and insufficient cash.
• The new sales, marketing, and distribution model, including the SCN acquisition, is unproven and may not produce the anticipated benefits, making future prospects difficult to evaluate.
• Integrating SCN's operations may be more difficult, costly, or time-consuming than expected, potentially disrupting business, leading to patient/employee loss, or other unintended consequences.
• The substantial indebtedness incurred for the SCN acquisition could adversely affect the company's business, financial condition, and results of operations, and there is no assurance it can be serviced.
• Contractual arrangements with physicians at SCN (and future acquisitions) may be found to violate state Corporate Practice of Medicine (CPM) laws or fee-splitting prohibitions, leading to restructuring, penalties, or loss of revenue.
• The new business model increases exposure to lawsuits, demands, claims, qui tam suits, governmental investigations, and audits, which could result in substantial financial penalties or reputational damage.
• Changes in the structure of and payment rates under private insurance, Medicare, Medicaid, or other government-based programs could materially adversely affect the company's business and financial results.
• The labor-intensive nature of the business, particularly with Sleep Optimization (SO) teams, poses risks related to recruiting qualified talent, managing labor costs, and potential shortages, which could increase operating costs and disrupt operations.
• There is a risk of potential Nasdaq delisting if the company fails to maintain compliance with the minimum stockholders' equity requirement, which could adversely affect stock price and ability to raise capital.
• Inflationary pressures may continue to increase costs for the company and its suppliers, potentially requiring price adjustments that could impact sales or demand.
• The Federal Reserve's response to inflation (elevated interest rates) could create unintended consequences for capital markets and the banking sector, impacting revenue, earnings, and access to capital.
• Supply chain challenges, though currently minimal for US-made appliances, could arise in the future.
• Geopolitical conflicts (e.g., War in Ukraine, Middle East hostilities) could disrupt commercial and capital markets, potentially leading to an economic recession and decreased demand for products.

Future Outlook

The company is pivoting its business strategy from a dentist-focused VIP model to a direct patient-focused model through strategic alliances and acquisitions of sleep specialty providers and centers. It expects to increase revenue from the SCN acquisition in the second half of 2025 and further in 2026, with the goal of ultimately achieving positive cash flow operations. The company plans to deploy additional Sleep Optimization (SO) teams to meet patient demand, with 1.5 teams currently deployed and two more expected by Q4 2025, and a fourth by Q1 2026. Each SO team is projected to potentially generate over $500,000 per month in collections with contribution margins above 50%. The company is also developing a revised management model for collaborations with sleep centers not interested in outright purchase, aiming for financial upside with limited capital expenditures. It is in active discussions for additional acquisitions and management opportunities.

Management Comments

• Our technologies and conventions represent a significant improvement in the treatment of mild to severe OSA versus other treatments such as continuous positive airway pressure (CPAP) or palliative oral appliance therapies.
• Our goal is to ramp up our systems and operations by strategically deploying additional personnel and resources to meet this demand (at SCN).
• We currently expect that some of SCNs locations, including the two already integrated, to be primary treatment hubs with larger patient capacities, with the remaining being referral centers (which could be relocated facilities) requiring less time and effort to integrate.
• Our operational plan is driven by our deployment of our Sleep Optimization (SO) teams.
• Based on the current volume of OSA patient demand, we believe the current markets served by SCN could support up to eight SO teams, and potentially more if certain planned growth initiatives meet expectations.
• We expect the current expansion at one facility and relocation of a second facility, coupled with the additional deployments of two new SO teams by mid-October 2025, will help reduce the backlog of patients seeking treatment. However, we do not believe we will be able to fully meet current demand until additional SO teams are fully deployed during 2026.
• Our initial average case revenue and acceptance rate for Vivos treatment at SCN to date suggest that each SO team could potentially generate collections in excess of $500,000 per month, net of adjustments, with contribution margins above 50%.
• We believe this revised management model can provide financial upside for our company with limited capital expenditures, and with what we believe are manageable risks.
• We believe that the overall benefit to our company of this model derives from the limited risks (as opposed to outright acquisitions) and generally low equipment and facility capital expenditures relative to the potential revenue opportunity.
• We believe this pipeline of potential acquisition and management activity, together with the experience gained from previous endeavors, will be a key driver of future accretive growth for us.

Industry Context

Vivos Therapeutics operates in the medical technology and services sector, specifically targeting the treatment of obstructive sleep apnea (OSA) and snoring. The company's strategic pivot from a dentist-centric training and support model to direct acquisition and management of sleep testing and treatment centers positions it more directly in the patient care pathway. This shift aims to capture higher-margin diagnostic and consulting revenues, aligning with a broader trend in healthcare towards integrated service delivery. The Vivos Method offers a non-surgical, time-limited alternative to traditional OSA treatments like CPAP, which typically require lifetime intervention, potentially appealing to patients seeking more definitive solutions. The company's focus on expanding its footprint through acquisitions and alliances in the sleep medicine market reflects a competitive landscape where innovation in treatment and efficient patient acquisition are crucial.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against industry standards. It broadly contrasts 'The Vivos Method' with 'CPAP and neuro-stimulation implants' by highlighting its typical 12-15 month treatment course and potential for non-lifetime intervention, unlike CPAP. No specific financial or operational benchmarks against competitors are provided.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in a lawsuit against Ortho-Tain, Inc. in the U.S. District Court for the District of Colorado, filed June 5, 2020, alleging false, threatening, and defamatory statements, interference with business relationships, and seeking injunctive relief and monetary damages. The Tenth Circuit dismissed Ortho-Tain's appeal for lack of jurisdiction on July 8, 2025, and denied a petition for rehearing on August 4, 2025.
• Ortho-Tain, Inc. filed a complaint against the company and others in the U.S. District Court for the Northern District of Illinois on July 22, 2020, alleging violation of the Lanham Act, civil conspiracy, and breach of contract. The District Court lifted a stay on March 2, 2023, and partially granted motions to dismiss on August 23, 2024. Discovery is ongoing, with a joint status report due by August 26, 2025.

Related Party Transactions

• On June 9, 2025, the company entered into a Securities Purchase Agreement (PIPE SPA) with V-Co Investors 2 LLC, an affiliate of New Seneca Partners Inc., a significant existing investor. V-Co 2 purchased common stock and warrants for total gross proceeds of $3.7 million.
• The $1.1 million bridge note entered into by the company and V-Co 2 on May 20, 2025, automatically converted into the June 2025 PIPE Offering.
• The June 2025 Warrants issued to V-Co 2 contain beneficial ownership limitations preventing Seneca or its affiliates from owning in excess of 19.99% of the then outstanding common stock upon exercise.
• The PIPE SPA requires the company to pay V-Co 2 $50,000 for its counsel's fees and expenses incurred in connection with the PIPE Offering.
• The June 2024 Private Placement involved V-CO Investors LLC, an affiliate of New Seneca Partners Inc., for gross proceeds of $7.5 million.
• The February 2024 Warrant Inducement Transaction was with the same institutional investor as the November 2023 Private Placement.

Stakeholder Impact

• **Shareholders**: Face significant dilution from recent and potential future equity raises. The 'going concern' warning and increased losses pose substantial risk to investment value. Nasdaq delisting risk could further impair liquidity and stock price. Potential for long-term value creation if the new business model succeeds, but this is highly uncertain.
• **Employees**: The business model pivot involves redeploying and refocusing training facilities and personnel, potentially impacting roles related to the legacy VIP model. The need to recruit and retain qualified Sleep Optimization (SO) teams suggests new opportunities but also potential for increased labor costs and competition for talent.
• **Customers (Patients)**: The new strategic model aims to provide better options for patients diagnosed with OSA by offering direct access to Vivos products and adjunctive therapies through acquired sleep centers like SCN. Increased patient demand at SCN suggests a positive impact on patient access, though current capacity constraints may lead to delays.
• **Dentists/Medical Providers**: The legacy VIP model (training and supporting dentists) is being phased out, meaning fewer new VIP dentists will be recruited. Existing VIPs will continue to receive support. The new model focuses on direct employment or collaboration with medical sleep specialists and nurse practitioners, shifting the relationship dynamic.
• **Creditors**: The company has incurred substantial senior secured debt, increasing its liabilities. Its ability to service this debt depends on future financial performance, which is uncertain given current losses and going concern issues. The pledge of AIM's membership interests as collateral provides some security to the lender.
• **Suppliers**: The company relies on third-party suppliers and contract manufacturers for raw materials and components. Concentration risk exists with five suppliers accounting for 57% of total purchases, but the company expects to maintain existing relationships.

Next Steps

• Continue to integrate SCN business into operations, with a goal of increasing SCN revenue in the second half of 2025 and further in 2026.
• Ramp up systems and operations at SCN by strategically deploying additional personnel and resources to meet patient demand.
• Deploy two additional Sleep Optimization (SO) teams during the fourth quarter of 2025.
• Deploy a fourth SO team sometime in the first quarter of 2026, aiming for a total of 4.5 SO teams operating.
• Continue to gather additional data to refine the SCN model and optimize operations and results.
• Implement the revised OSA provider management model, with the first agreement with MISleep Solution LLC in Auburn Hills, Michigan, estimated to open in October 2025.
• Continue active discussions with potential acquisition targets and management opportunities for sleep centers and medical sleep specialists.
• File a registration statement under the Securities Act covering the resale of the June 2025 Warrants no later than 45 days following the closing of the June 2025 PIPE SPA (extended by 30 days as of July 24, 2025).
• Use commercially reasonable best efforts to cause the registration statement for the June 2025 Warrants to be effective within 90 days of the closing of the June 2025 PIPE SPA (extended by 30 days as of July 24, 2025).
• Continue to monitor and adjust manufacturing and sourcing strategy in response to U.S. trade policy changes and tariffs.
• Revisit standard pricing for appliance products in 2025 due to inflationary pressures.
• Continue with discovery in the Illinois Ortho-Tain legal case, with a joint status report due by August 26, 2025.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by widening net losses, declining revenue, and a explicit 'substantial doubt' about its ability to continue as a going concern. While a strategic pivot and recent acquisition (SCN) are underway, the new business model is unproven, and initial results from a prior alliance were disappointing. The company's increasing reliance on debt and equity raises to fund operations and acquisitions, coupled with significant integration risks and potential regulatory challenges (CPM laws), indicates a highly speculative and precarious investment. For a seasoned investor, the current financial instability and high operational risks outweigh the potential long-term upside, making a 'sell' recommendation prudent to avoid further capital erosion.

Keywords

Vivos Therapeutics, VVOS, SEC Filing, 10-Q, Obstructive Sleep Apnea, OSA, Sleep Center of Nevada, SCN Acquisition, Medical Technology, Oral Appliances, Sleep Disorders, Financial Results, Net Loss, Revenue Decline, Going Concern, Strategic Pivot, Debt Financing, Private Placement, Corporate Practice of Medicine, Healthcare Regulation, Nasdaq Listing, Risk Factors